Zydus Lifesciences moves up on getting USFDA`s approval for ZITUVIMET
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 589.45, up by 4.85 points or 0.83% from its previous closing of Rs. 584.60 on the BSE.
The scrip opened at Rs. 585.05 and has touched a high and low of Rs. 591.05 and Rs. 585.05 respectively. So far 562 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022.
Last one week high and low of the scrip stood at Rs. 591.05 and Rs. 570.35 respectively. The current market cap of the company is Rs. 59173.45 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.95% and 7.07% respectively.
Zydus Lifesciences has received approval from U.S. Food and Drug Administration (USFDA) for its New Drug Application (NDA) for ZITUVIMET (Sitagliptin and Metformin hydrochloride) tablets, 50 mg/500 mg and 50 mg/1000 mg.
ZITUVIMET contains active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The approval of ZITUVIMET is based on research, development, regulatory, and manufacturing work performed by Zydus teams. ZITUVIMET has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards. ZITUVIMET is compliant with current USFDA standards of Nitrosamines in Sitagliptin containing products.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
